CD274 and urinary bladder carcinoma: Anticancer immunotherapy is vital in the treatment strategy of bladder cancer, and immune checkpoint inhibitors (ICIs), anti-PD1 or anti-PD-L1 antibodies, have exhibited efficacy in clinical trials alone or in conjunction with chemotherapy36.